Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

STRO-006

Other · developed by Sutro Biopharma

Phase 1 Most advanced trial
STRO Developer
1 Registered trials

What is STRO-006?

STRO-006 is a drug studied in head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal cancer, gastric cancer, colorectal cancer, endometrial cancer, urothelial carcinoma and breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
Sutro Biopharma, Inc. (STRO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07807345 Phase 1 Head & Neck Squamous Cell Carcinoma Recruiting STRO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerColorectal CancerEndometrial CancerEsophageal CancerGastric CancerHead & Neck Squamous Cell CarcinomaNon-Small Cell Lung CancerUrothelial Carcinoma (UC)

More from Sutro Biopharma

Follow STRO, the company behind STRO-006

See STRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

STRO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.